m6A-centered Crosstalk Information
Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
| Crosstalk ID |
M6ACROT05966
|
[1] | |||
m6A modification
CCAT2
CCAT2
VIRMA
Methylation
 : m6A sites
Direct
Enhancement
Non-coding RNA
CCAT2
MIR145
lncRNA miRNA circRNA
|
|||||
| m6A Modification: | |||||
|---|---|---|---|---|---|
| m6A Regulator | Protein virilizer homolog (VIRMA) | WRITER | |||
| m6A Target | Colon cancer associated transcript 2 (CCAT2) | ||||
| Epigenetic Regulation that have Cross-talk with This m6A Modification: | |||||
| Epigenetic Regulation Type | Non-coding RNA (ncRNA) | ||||
| Epigenetic Regulator | Colon cancer associated transcript 2 (CCAT2) | LncRNA | View Details | ||
| Regulated Target | MicroRNA 145 (MIR145) | View Details | |||
| Crosstalk Relationship | m6A → ncRNA | Enhancement | |||
| Crosstalk Mechanism | m6A regulators directly modulate the functionality of ncRNAs through specific targeting ncRNA | ||||
| Crosstalk Summary | In prostate cancer, VIRMA-mediated m6A modification of Colon cancer associated transcript 2 (CCAT2) can upregulate CCAT2, which act as a sponge for MicroRNA 145 (MIR145) to upregulate the expression of MYC. | ||||
| Responsed Disease | Prostate cancer | ICD-11: 2C82 | |||
| Responsed Drug | Actinomycin D | ||||
| Cell Process | RNA stability | ||||
In-vitro Model |
22Rv1 | Prostate carcinoma | Homo sapiens | CVCL_1045 | |
| LNCaP | Prostate carcinoma | Homo sapiens | CVCL_0395 | ||
| VCaP | Prostate carcinoma | Homo sapiens | CVCL_2235 | ||
| DU145 | Prostate carcinoma | Homo sapiens | CVCL_0105 | ||
| PC-3 | Prostate carcinoma | Homo sapiens | CVCL_0035 | ||
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
| 2C82: Prostate cancer | 1 Compound(s) Regulating the Disease | Click to Show/Hide the Full List | ||
 Compound Name |
CC-94676 | Phase 1 | [2] | |
|---|---|---|---|---|
| External Link | ||||
References